Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zuberitamab + methotrexate + thiotepa + orelabrutinib
- Development stage
- Phase 2
- Lead developer
- Ou Bai
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
HiMTO is a combination chemoimmunotherapy regimen consisting of the anti-CD20 monoclonal antibody zuberitamab, the antimetabolite methotrexate, the alkylating agent thiotepa, and the Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib. It is being investigated as an induction therapy for patients with the MCD subtype of diffuse large B-cell lymphoma (DLBCL), a molecularly defined subgroup characterized by MYD88 and CD79B mutations. The regimen combines the B-cell depleting activity of zuberitamab with the cytotoxic effects of methotrexate and thiotepa, and the targeted inhibition of B-cell receptor signaling by orelabrutinib. This combination is particularly relevant for MCD subtype DLBCL, which often exhibits high rates of central nervous system involvement and reliance on BTK-mediated signaling.
- Other names
- HiMTO regimen
02
Targets
Beyond the preview
Go deeper on zuberitamab + methotrexate + thiotepa + orelabrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zuberitamab + methotrexate + thiotepa + orelabrutinib.